According to Zhitong Finance App News, Alice (688578.SH) disclosed the 2026 semi-annual report. During the reporting period, the company achieved operating income of 3.32 billion yuan, an increase of 39.85%; net profit attributable to shareholders of listed companies was 1,541 billion yuan, up 46.57% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 1,367 billion yuan, an increase of 50.99% year on year; basic income per share was 3.42 yuan; the company plans to pay a cash dividend of 6 yuan (tax included) for every 10 shares.

The main reason for the increase in performance was that during the reporting period, the company actively exploited the synergy of commercial products, formed a multi-level development engine, and gave full play to the company's platform advantages in the field of oncology. With the support and coverage of the national health insurance policy, with outstanding differentiated clinical advantages, revenue related to vormetinib mesylate tablets (total revenue of 313,78184,000 yuan during the reporting period), golerecide citrate tablets (total revenue of 13,02368 million yuan during the reporting period), and the commercial promotion product Platinib capsules (total revenue of 51.7098 million yuan during the reporting period) continued to grow, driving the company's operating performance to continue to rise.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.